Daklinza (daclatasvir) / BMS 
Welcome,         Profile    Billing    Logout  
 32 Diseases   5 Trials   5 Trials   1782 News 


«12...234567891011121314»
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Review, Journal:  Management of acute HCV infection in the era of direct-acting antiviral therapy. (Pubmed Central) -  Jul 17, 2019   
    The Review also discusses the 2016 AASLD-IDSA and EASL recommendations for acute HCV infection management in light of available evidence and highlights key differences in study populations and design that influence interpretation. We focus on populations at high risk of HCV transmission and acquisition, including people who inject drugs and HIV-positive men who have sex with men, and highlight the potential effects of diagnosis and treatment of acute HCV infection in contributing to HCV elimination.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Review, Journal:  Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. (Pubmed Central) -  Jul 4, 2019   
    According to the documented results, there is hope that this disease can be effectively cured in Pakistan, although a few concerns still remain. The aim of this article is to review the effectiveness of DAAs and the current status of this treatment against HCV genotype 3 infection in Pakistan; various factors associated with SVR; its limitations as an effective treatment regime; and future implications.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Efficacy and Safety of Direct Acting Antiviral Therapy for Chronic Hepatitis C in Thalassemic Children. (Pubmed Central) -  Jun 5, 2019   
    Altogether, our findings indicate that the proposed method is a reliable and accurate new tool for high-throughput screening of large patient cohorts that could be readily used to optimize treatment modalities and reduce drug-related toxicities. DAA in adult dosage are safe and effective for treatment of chronic hepatitis C (genotype 3) in pediatric β-thalassemic major population.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Clinical, Journal, Real-World Evidence:  Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China. (Pubmed Central) -  May 31, 2019   
    ...A total of 226 patients receiving SOF plus daclatasvir (DCV), ledipasvir (LDV), or velpatasvir (VEL) were enrolled from December 2014 to June 2017...NS5B polymerase inhibitor SOF plus one of the NS5A inhibitors, such as DCV, LDV, or VEL for 12 weeks was associated with high SVR12 rates and well tolerated in HCV-infected patients without cirrhosis. Moreover, patients with DAAs failure should be retreated with more effective regimens like SOF/VEL.
  • ||||||||||  Copegus (ribavirin) / Bausch Health, Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. (Pubmed Central) -  May 24, 2019   
    We herein report, for the first time, the successful retreatment with glecaprevir and pibrentasvir, of three hemodialysis patients with genotype 1 or 2 HCV infection, who had previously failed to respond to combination therapy with an HCV-NA5A inhibitor (daclatasvir) and an HCV protease inhibitor (asunaprevir). The findings from the present study suggested that SOF/DCV (with or without RBV) regimen exhibited high effectiveness, was well tolerated in the treatment of chronic HCV GT 4, and revealed itself as a better option for patients with advanced liver disease, making the eradication of HCV a more realistic target to achieve.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Clinical, Journal:  SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient. (Pubmed Central) -  Apr 24, 2019   
    Blood test alterations returned normal after one week of treatment suspension, HCV viremia remained suppressed after 4, 12 and 24 weeks proving HCV eradication. If confirmed, these data could suggest that higher doses of DCV, if tolerated, might be employed in short-time HCV-GT3 treatment.
  • ||||||||||  Daklinza (daclatasvir) / BMS
    Journal:  A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus. (Pubmed Central) -  Apr 19, 2019   
    The best inhibitor 27a was found to be 3-fold more potent (GT1b EC = 0.003 nM) than daclatasvir (GT1b EC = 0.009 nM) against GT1b, and no detectable in vitro cytotoxicity was observed (CC > 50 μM). Pharmacokinetic studies demonstrated that compound 27a had an excellent pharmacokinetic profiles with a superior oral exposure and desired bioavailability after oral administration in both rats and dogs, and therefore it was selected as a developmental candidate for the treatment of HCV infection.
  • ||||||||||  Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
    Biomarker, Journal:  Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During DAA Therapy. (Pubmed Central) -  Mar 25, 2019   
    An enhanced interferon signature is observed at baseline in liver and blood of patients who achieve SVR as compared to those who experience a virological breakthrough. The findings suggest innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy.
  • ||||||||||  Clinical, Journal:  Multitarget Direct-Acting Antiviral Therapy Is Associated With Superior Immunologic Recovery in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. (Pubmed Central) -  Dec 18, 2018   
    We analyzed peripheral blood mononuclear cells (PBMCs) at baseline and at the time of sustained viral response (SVR) from subjects treated with three different combination DAA regimens: daclatasvir (DCV) and asunaprevir (ASV) for 24 weeks (CONQUER 2-DAA), DCV/ASV/beclabuvir (BCV) for 12 weeks (CONQUER 3-DAA), and sofosbuvir (SOF) and ledipasvir (LDV) for 12 weeks (ERADICATE study)...We showed that different DAA-based therapies have different immunologic outcomes after successful HCV treatment in patients coinfected with HIV/HCV. This information will be beneficial for providers when selecting the regimens for patients coinfected with HIV/HCV.
  • ||||||||||  Daklinza (daclatasvir) / BMS, Sovaldi (sofosbuvir) / Gilead
    Trial completion date:  Management of Decompensated HCV Cirrhotic Patients (clinicaltrials.gov) -  Dec 5, 2018   
    P=N/A,  N=80, Completed, 
    This information will be beneficial for providers when selecting the regimens for patients coinfected with HIV/HCV. Trial completion date: Jan 2018 --> Jun 2018
  • ||||||||||  Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
    Trial initiation date:  Early Post-marketing Study of Daclatasvir (Daklinza (clinicaltrials.gov) -  Aug 25, 2018   
    P=N/A,  N=30, Not yet recruiting, 
    Phase classification: P=N/A --> P1 Initiation date: Jul 2018 --> Nov 2018